235 related articles for article (PubMed ID: 7986107)
21. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
22. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
23. Adaptive design may hasten clinical trials.
Schmidt C
J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
[No Abstract] [Full Text] [Related]
24. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
25. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
26. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
27. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
[TBL] [Abstract][Full Text] [Related]
28. Design issues in dose-finding Phase I trials for combinations of two agents.
Fan SK; Venook AP; Lu Y
J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
[TBL] [Abstract][Full Text] [Related]
29. [Combined antineoplastic agents guidelines--guidelines for clinical trials I/II].
Gan To Kagaku Ryoho; 2004 Apr; 31(4):657-65. PubMed ID: 15114719
[No Abstract] [Full Text] [Related]
30. Exisulind Cell Pathways.
Griffiths GJ
Curr Opin Investig Drugs; 2000 Nov; 1(3):386-91. PubMed ID: 11249724
[TBL] [Abstract][Full Text] [Related]
31. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
32. GTI-2040. Lorus Therapeutics.
Orr RM
Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
[TBL] [Abstract][Full Text] [Related]
33. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
34. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
35. [Phase II clinical trial of anticancer drugs].
Izumi T; Kurihara M
Gan To Kagaku Ryoho; 1991 Jul; 18(9):1493-8. PubMed ID: 1854220
[TBL] [Abstract][Full Text] [Related]
36. [A tentative of guideline for phase III study and its problems in clinical aspect].
Nakao I
Gan To Kagaku Ryoho; 1984 Mar; 11(3):395-403. PubMed ID: 6703719
[TBL] [Abstract][Full Text] [Related]
37. Ethical issues in cooperative cancer therapy trials from a statistical viewpoint. II. Specific issues.
Shuster JJ; Krischer JP; Boyett JM
Am J Pediatr Hematol Oncol; 1985; 7(1):64-70. PubMed ID: 4037245
[TBL] [Abstract][Full Text] [Related]
38. [Phase III study].
Furuse K
Gan To Kagaku Ryoho; 1995 Apr; 22(5):611-5. PubMed ID: 7717712
[TBL] [Abstract][Full Text] [Related]
39. Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
Markman M
Cancer; 2010 Nov; 116(22):5116-8. PubMed ID: 20665504
[No Abstract] [Full Text] [Related]
40. P-value calculation for multistage phase II cancer clinical trials.
Jung SH; Owzar K; George SL; Lee T
J Biopharm Stat; 2006; 16(6):765-75; discussion 777-83. PubMed ID: 17146978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
